

From: Dobbs, Donald <Donald.Dobbs@fda.hhs.gov>
Sent: Friday, April 13, 2018 5:28 AM
To: CLEAR Alliance <info@clearalliance.org>
Subject: Your letter to the FDA

Dear Mr. Thompson:

Thank you for writing to the Food and Drug Administration (FDA). This is in response to your February 15, 2018, letter requesting an explanation of the laws, rules, and regulations regarding the sale and use of CBD (cannabidiol) and THC (tetrahydrocannabinol). Your letter was forwarded to the Division of Drug Information in FDA's Center for Drug Evaluation and Research (CDER) for a response.

The FDA has not approved any product containing or derived from botanical marijuana for any indication. The FDA is aware that multiple states have either passed laws that remove state restrictions on the medical use of marijuana and its derivatives or are considering doing so. We cannot comment on those state laws. Therefore, we are only able to respond to Question 7 in your letter that asks whether FDA has approved CBD to be infused in food or drinks.

FDA has concluded that it is a prohibited act to introduce or deliver for introduction into interstate commerce any food (including any animal food or feed) to which THC or CBD has been added. For background information on this determination, please see the response to Question 14 on our website at: <https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm421168.htm#legal>. Additional information about FDA and marijuana and marijuana-derived products can be found at this site as well.

Also, please note that the Drug Enforcement Administration (DEA) is the federal agency responsible for enforcing the controlled substance laws and regulations in the United States and, as such, you may also wish to contact them for information. The home page for their website can be found at: <http://www.dea.gov/index.shtml>.

If you have drug related questions or concerns in the future, you can call us at 301-796-3400, toll free at 855-543-3784, e-mail us at druginfo@fda.hhs.gov or write to:

Food and Drug Administration
Division of Drug Information
Hillandale Building
10001 New Hampshire Ave
Silver Spring, MD 20993-0002

Thank you again for writing.

Sincerely,
/s/
Donald Dobbs
Division of Drug Information
Office of Communications
Center for Drug Evaluation and Research
Food and Drug Administration